When was Avista Pharma founded?

Avista Pharma was founded in 2015.

Where is Avista Pharma located?

Avista Pharma is headquartered in Durham, United States.

Where does Avista Pharma rank among its competitors?

Avista Pharma ranks 113th amongst 371 active competitors, of which 15 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Nucleus RadioPharma, which secured an undisclosed amount in Jun, 2024.

Who are the top competitors of Avista Pharma?

Avista Pharma's top competitors include Concord Biotech, Aizant and Almac Group. Among them, Nucleus RadioPharma secured the most recent funding round in June, 2024.

Avista Pharma - 2026 Company Profile, Funding & Competitors

Q: Is Avista Pharma an acquired company?

Avista Pharma got acquired by Cambrex on Nov 20, 2018.

Avista Pharma is an acquired company based in Durham (United States), founded in 2015. It operates as a Leading hosting automation software providing web server and website management tools. Avista Pharma has raised $252M in funding. The company has 371 active competitors, including 15 funded and 88 that have exited. Its top competitors include companies like Concord Biotech, Aizant and Almac Group.

Company Details

Leading hosting automation software providing web server and website management tools. It offers a comprehensive and user-friendly GUI designed to help IT specialists efficiently manage web, DNS, mail, and other essential services. This software simplifies the complexities of web hosting, providing secure and simple solutions for managing web servers and websites. It is a hosting control panel that empowers users to create domains and set up web hosting with ease. The platform offers a knowledge base, developer blog, and forum to support its users. It is a B2B tech company offering software solutions.

Website: avistapharma.com
Social
Email ID: *****@avistapharma.com

Key Metrics

Founded Year

2015

Location

Durham, United States

Stage

Acquired

Total Funding

$252M

Investors

Ampersand Capital

Ranked

113^th among 371 active competitors

Investment & Acquisitions

Solid Forms Solutions

Similar Companies

Concord Biotech & 416 more

Exit Details

Acquired by Cambrex (Nov 20, 2018)

View Avista Pharma's full profile

Avista Pharma got acquired by Cambrex on Nov 20, 2018 at an acquisition amount of $*****.

Click here to take a look at Avista Pharma's acquisition in detail

Avista Pharma has raised a total funding of $252M. Avista Pharma has 1 institutional investor.

View details of Avista Pharma's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Avista Pharma include Concord Biotech, Aizant and Almac Group. Here is the list of Top 10 competitors of Avista Pharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Concord Biotech 2000, Ahmedabad (India), Public	CDMO focused on manufacturing API	-	Quadria Capital, Helix Investments & 18 others	65/100
2nd	Aizant 2005, Hyderabad (India), Series A	Company offering contract development services for small molecules	$16.8M	Zephyr Management, Zephyr Peacock & 39 others	60/100
3rd	Almac Group 2001, Craigavon (United Kingdom), Series D	CRAMS company offering preclinical development and CDMO services, also offering companion diagnostic development	$339M	Genomic Health, Gates & 4 others	57/100
4th	Nucleus RadioPharma 2022, Rochester (United States), Series A	CDMO focused on providing of radiopharmaceuticals manufacturing and supply chain services	$72.1M	Eclipse, AstraZeneca & 7 others	54/100
5th	Indoco Remedies 1947, Mumbai (India), Public	Provider of APIs manufacturing and formulation services	-	Baring Private Equity Partners	54/100
6th	Wanbury Limited 1990, Mumbai (India), Public	Manufacturer of anti-diabetic drugs	-	-	53/100
7th	Biophore 2007, Hyderabad (India), Seed	Development and manufacturing of niche pharmaceutical products for the generic industry	$2.74M	Ontario & 6 others	53/100
8th	Galenicum 2003, Barcelona (Spain), Late Stage	Turnkey solutions for drug development, manufacturing and regulatory approvals	-	Peninsula Capital	52/100
9th	Amino 1958, Frellstedt (Germany), Unfunded	CDMO focused on amino acids and small molecules	-	-	51/100
10th	Aptuit 2004, Greenwich (United States), Acquired	Pioneering drug discovery and development, accelerating concept to cure	$14.2M	Temasek, Welsh, Carson, Anderson & Stowe & 1 others	50/100
113th	Avista Pharma 2015, Durham (United States), Acquired	Leading hosting automation software providing web server and website management tools	$252M	Ampersand Capital	30/100